Ultragenyx Pharmaceutical Inc. Revenue 2016–2025
Ultragenyx Pharmaceutical Inc. annual/quarterly revenue history and growth rate from 2016 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Ultragenyx Pharmaceutical Inc. revenue for the quarter ending March 31, 2026 was 136.0 M, a 2.16% decrease year-over-year.
- Ultragenyx Pharmaceutical Inc. revenue for the twelve months ending March 31, 2026 was 601.4 M, a 21.89% increase year-over-year.
- Ultragenyx Pharmaceutical Inc. annual revenue for 2025 was 673.0 M, a 20.18% increase from 2024.
- Ultragenyx Pharmaceutical Inc. annual revenue for 2024 was 560.0 M, a 29.03% increase from 2023.
- Ultragenyx Pharmaceutical Inc. annual revenue for 2023 was 434.0 M, a 19.45% increase from 2022.
- Ultragenyx Pharmaceutical Inc. annual revenue for 2022 was 363.3 M.
Ultragenyx Pharmaceutical Inc. (RARE) — Frequently Asked Questions
Ultragenyx Pharmaceutical Inc. (RARE) is a publicly traded US company. It has a market capitalization of $2.27B. In fiscal 2025 it reported revenue of $673M and net income of -$575M. Explore RARE's stock price, financial statements, earnings history, margins and key ratios below.
What is Ultragenyx Pharmaceutical Inc.'s market cap?
Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalization of $2.27B.
What is the RARE stock price?
RARE trades at $23.05 (+0.35% on the day).
How much revenue does Ultragenyx Pharmaceutical Inc. make?
Ultragenyx Pharmaceutical Inc. reported revenue of $673M in fiscal 2025.
Is RARE profitable?
In fiscal 2025, Ultragenyx Pharmaceutical Inc. reported net income of -$575M.